Pembrolizumab plus axitinib versus sunitinib for advanced clear cell renal cell carcinoma: 5-year survival and biomarker analyses of the phase 3 KEYNOTE-426 trialBrian I. Rini, Thomas Powles, Tom Waddell et al.|Nature Medicine|2025Cited by 44
Association of gene expression with clinical outcomes in patients with renal cell carcinoma treated with pembrolizumab in KEYNOTE-427.David F. McDermott, Michael B. Atkins, Jae‐Lyun Lee et al.|Journal of Clinical Oncology|2020Cited by 14